Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02484690 · ClinicalTrials.gov registry record · Phase 2
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 273
- Enrollment target
NCT02484690 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 273 participants.
The verdict
NCT02484690, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 273 participants
- Enrollment target
Study Summary
This multiple-center, multiple-dose and regimen, randomized, double-masked active comparator-controlled, double-masked, five parallel group, 36-week study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of faricimab (RO6867461) in participants with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The study was designed to allow the evaluation of RO6867461 in a treatment-naive population (comparison of Arms A, B, C, and D) and an anti-VEGF-incomplete responder population that met a predefined criterion at Week 12 (comparison between Arms A and E). Only one eye per participant was chosen as the study eye.
Interventions
- DRUG Faricimab
- DRUG Ranibizumab
- DRUG Sham Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2015-08-11 |
| Est. Completion | 2017-09-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02484690
The ClinicalTrials.gov registry entry for NCT02484690 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 273 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Faricimab is the first listed.
NCT02484690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02484690 about?
NCT02484690 is a clinical study titled "A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)". This multiple-center, multiple-dose and regimen, randomized, double-masked active comparator-controlled, double-masked, five parallel group, 36-week study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of faricimab (RO6867461) in participants with choroidal neovascularization...
What is the current status of trial NCT02484690?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 273 participants. The study started on 2015-08-11. Estimated completion is 2017-09-26.
What interventions are being tested in trial NCT02484690?
The interventions under investigation include: Faricimab (DRUG), Ranibizumab (DRUG), Sham Procedure (DRUG).
Who is sponsoring clinical trial NCT02484690?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.